跳轉至內容
Merck
全部照片(1)

文件

06863

Sigma-Aldrich

甘氨酰去氧胆酸

≥96.0% (TLC)

同義詞:

N-(3α,7β-二羟基-5β-cholan-24-oyl）甘氨酸, N-[(3α, 5β, 7β）-3,7-二羟基-24-氧代胆甾烷-24-基 ] 甘氨酸, GUDCA, 乌索脱氧胆基甘氨酸, 甘氨酰脱氧胆酸

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C26H43NO5
CAS號碼:
64480-66-6
分子量：:
449.62
MDL號碼:
MFCD00137427
分類程式碼代碼:
12161900
PubChem物質ID:
329748294
NACRES:
NA.25

生物源

synthetic

化驗

≥96.0% (TLC)

形狀

powder

官能基

carboxylic acid

SMILES 字串

[H][C@@]12[C@]([C@](CC[C@@H](O)C3)(C)[C@]3([H])C[C@@H]2O)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCC(NCC(O)=O)=O

InChI

1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

InChI 密鑰

GHCZAUBVMUEKKP-XROMFQGDSA-N

相關類別

應用


  • Glycoursodeoxycholic Acid Alleviates Arterial Thrombosis via Suppressing Diacylglycerol Kinases Activity in Platelet.: Highlights the therapeutic potential of Glycoursodeoxycholic acid in alleviating arterial thrombosis by inhibiting diacylglycerol kinase activity in platelets (Yang et al., 2024).

生化／生理作用

来源于酰基甘氨酸的次级胆汁酸。据报道甘氨脱氧胆酸 (GUDCA) 具有细胞保护和抗炎作用。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Kazuya Maeda et al.
Molecular pharmaceutics, 3(1), 70-77 (2006-05-12)
Ursodeoxycholate (UDCA) is widely used for the treatment of cholestatic liver disease. After oral administration, UDCA is absorbed, taken up efficiently by hepatocytes, and conjugated mainly with glycine to form glycoursodeoxycholate (GUDC) or partly with taurine to form tauroursodeoxycholate (TUDC)
Sandra L Silva et al.
Neuropharmacology, 62(7), 2398-2408 (2012-03-01)
Neuronal oxidative damage and cell death by unconjugated bilirubin (UCB) showed to be mediated by overstimulation of glutamate receptors and nitric oxide (NO) production, which was abrogated by the bile acid glycoursodeoxycholic acid (GUDCA). Microglia, a crucial mediator of CNS
Jingyu Yan et al.
Scientific reports, 7(1), 4211-4211 (2017-06-25)
Cholestasis is a clinical disorder defined as an impairment of bile flow, and that leads to toxic bile acid (BA) accumulation in hepatocytes. Here, we investigated the hepatoprotective effect of Yinchenhaotang (YCHT), a well-known formulae for the treatment of jaundice
A Roda et al.
Pharmaceutical research, 11(5), 642-647 (1994-05-01)
A new enteric-coated formulation of sodium ursodeoxycholate was prepared and administered to man. The barrier film disintegrates and releases the drug only at pH > or = 5.5. The sodium salt of glycoursodeoxycholate was also prepared and encapsulated like ursodeoxycholate.
A Roda et al.
The Journal of biological chemistry, 258(10), 6362-6370 (1983-05-25)
The relationship between chemical structure and the concentration at which self-association occurs in water or in 0.15 M Na+ ion was examined for more than 50 bile salts and bile salt analogues varying in substituents on the steroid nucleus or
查看所有相關論文

條款

HPLC Separation of Bile Acids with Ascentis Express C18

Investigate bile acid roles in gut hormone profiles and glycemic control, vital for clinical labs exploring potential mechanisms.

相關內容

Bile Acids Kit for LC-MS

Bile Acids (BA) are synthesized in the liver and play important roles in cholesterol homeostasis, absorption of vitamins and lipids, and various key metabolic processes.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務